[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exacerbation-of-copd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exacerbation-of-copd":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100601572","using-multiomics-to-define-mechanisms-of-rhinovirus-induced-chronic-obstructive-pulmonary-disease-exacerbations-to-develop-novel-therapies-and-therapeutic-targets-100601572",false,"NCT07112235","Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets","Using Multiomics to Define Mechanisms of RhinoVirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets","MRVCOPD","Inclusion Criteria for COPD subjects\n\n* Male or female sex\n* Age ≥40 years and ≤75 years at the time of signing the consent form\n* Medical history or clinical diagnosis of COPD\n* Significant smoking history, defined as:\n\n  * Cumulative smoking history of at least 20 pack years\n  * Permitted to currently use, or have history of use of, e-cigarettes\u002Fvapes\n* COPD spirometry criteria:\n\n  * Post bronchodilator FEV1 of \\\u003C80% and ≥50% predicted for age and height (equivalent to GOLD criteria stage 2 for 'Moderate' severity COPD9)\n  * Post-bronchodilator FEV1\u002FFVC ratio \\\u003C0.7\n  * β-agonist reversibility: an improvement of less than 12% predicted FEV1 and less than 200mL after 200 micrograms of salbutamol or equivalent short acting beta-2 agonist bronchodilator.\n* History of acute exacerbations of COPD as defined by the participant answering \"yes\" to the question: \"do your COPD symptoms get noticeably worse when you catch a cold?\"\n* Clinically stable with no COPD exacerbations within 8 weeks prior to enrolment\n* Permitted to take short and long-acting bronchodilators including beta agonists and muscarinic antagonist inhalers\n* Co-morbidity criteria:\n\n  * Permitted to have a past medical history of asthma, allergic rhinitis and seasonal rhinitis, but not currently active within 8 weeks prior to enrolment\n  * Absence of current or previous history of significant respiratory disease, other than COPD, asthma and allergic rhinitis\n* Permitted to have a positive skin test for atopy\n\nInclusion Criteria for non-smoking controls\n\n* Male or female sex\n* Age ≥ 40 years and ≤ 75 years at the time of signing the consent form\n* No history or clinical diagnosis of COPD\n* No significant smoking history, defined as:\n\n  * Less than 5 pack year cumulative smoking history\n  * Has not smoked or used e-cigarettes\u002Fvapes in the last 1 year\n* Controls spirometry criteria\n\n  * FEV1 of ≥80% predicted for age and height\n  * FEV1\u002FFVC ratio ≥0.7\n* Co-morbidity criteria:\n\n  * Permitted to have a past medical history of asthma, allergic rhinitis and seasonal rhinitis, but not currently active in the 8 weeks prior to enrolment\n  * Absence of current or previous history of significant respiratory disease, other than asthma and allergic rhinitis\n* Permitted to have a positive skin test for atopy.\n\nInclusion Criteria for smoking controls\n\n• Identical to non-smoking controls, with the exception of smoking history:\n\n* Cumulative smoking history of at least 20 pack years.\n* Permitted to currently use, or have history of use of, e-cigarettes\u002Fvapes\n\nExclusion Criteria:\n\n* Participants with other causes of chronic airflow limitation, including but not limited to:\n\n  * Bronchiectasis including cystic fibrosis\n  * Bronchiolitis obliterans\n  * Carcinoma of the bronchus\n  * Fibrosis such as tuberculosis (TB), idiopathic pulmonary fibrosis\n* Presence of any significant systemic disease, that in the opinion of the investigator would (a) make participation in the study unduly risky, or (b) significantly interfere with important outcomes being measured.\n\n  * For example, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric conditions.\n* Pregnant, planning to become pregnant, testing positive for pregnancy at the screening visit test, or nursing females during and within 30 days of treatment.\n* Treatment with oral, inhaled or nasal corticosteroids within 8 weeks prior to enrolment.\n* Treatment with antibiotics in the 8 weeks preceding enrolment.\n* Treatment with nasal medications, anti-leukotrienes, anti-histamine at the time of the study.\n* Presence (at screening) of serum rhinovirus-A16 neutralising antibodies in a titre \\>1:2.\n* Individuals with close contact to at risk patient group, including:\n\n  * Infants (less than 6 months);\n  * The extremely elderly or infirm;\n  * Pregnant and\u002For breastfeeding women;\n  * Patients with immunosuppression (e.g., human immunodeficiency virus (HIV), transplant recipients on anti-rejection medications, those undergoing chemo- or immuno-therapy).\n  * Other factors that in the opinion of the investigator are considered a risk.\n* Participation in other clinical research studies that, in the opinion of the investigator, would (a) make participation in the study unduly risky, or (b) significantly interfere with important outcomes being measured in this or other studies, or (c) present an unacceptable visit burden to the participant.",true,"ALL","40 Years","75 Years",{"count":22,"type":23},50,"ESTIMATED","OBSERVATIONAL","The goal of this study is to examine exacerbations of chronic obstructive pulmonary disease (COPD) caused by a common cold virus called rhinovirus, to identify new treatments. Exacerbations are flare-ups of respiratory symptoms which are a major cause of ill health in people with COPD, and are most commonly caused by viruses.\n\nThe main questions the study aims to answer are:\n\n* What processes in the body occur in response to rhinovirus infection, and do the differences between people with COPD and healthy volunteers explain why people with COPD develop more severe illness and exacerbations?\n* Can treatments be identified that target these processes to reduce the severity and frequency of exacerbations in people with COPD?\n\nThe study will compare eligible participants with COPD to healthy volunteers, and will involve intentionally infecting each participant with rhinovirus in a controlled environment. They will undergo baseline investigations prior to infection including a first bronchoscopy. Post-infection each participant will undergo a range of tests, including a second bronchoscopy, to compare how processes in the body, and especially the lungs, differ between people who do and do not have COPD.",[27,28,29],"COPD (Chronic Obstructive Pulmonary Disease)","Rhinovirus Infection","Exacerbation of COPD",[31,32,33,34,35,36],"COPD","Chronic Obstructive Pulmonary Disease","Exacerbation","Multiomics","Rhinovirus","Viral challenge study","RECRUITING","2026-04-13",{"date":40,"type":41},"2026-04-14","ACTUAL",{"date":43,"type":41},"2025-10-08",{"date":45,"type":23},"2027-03-31",{"name":47,"class":48},"Imperial College London","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":49},"100587544","phase-4-do-blood-tests-help-to-decide-which-patients-with-flares-of-chronic-obstructive-pulmonary-disease-copd-need-antibiotics-and-steroids-100587544","NCT06929767","Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotics and Steroids?","Biomarker Guided Decision-making in Acute Exacerbation of COPD: a Feasibility Study","Bidex","Inclusion Criteria:\n\n* Outpatients with a known diagnosis of COPD (must have prior spirometry documenting FEV1\u002FFVC post-bronchodilator \\\u003C 0.7 or documented respirologist-diagnosis of COPD)\n* Presenting with AECOPD, defined as an increase in respiratory symptoms necessitating an increase in medications\n* Consent provided\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n* new infiltrate on chest x-ray day of randomization\n* temperature ≥ 38.0 ◦C taken orally day of randomization\n* positive blood culture day of randomization\n* co-morbid asthma or severe bronchiectasis\n* acute heart failure day of randomization\n* known immunosuppression including the use of chronic glucocorticoids day of randomization\n* allergy\u002Fabsolute contraindication to the use of oral steroids\n* planned pregnancy or currently pregnant\n* COVID positive",{"count":59,"type":23},80,"INTERVENTIONAL",[62],"PHASE4","The goal of this clinical trial is to see if the use of two simple blood tests: C reactive protein and eosinophils, can reduce the use of steroids and antibiotics in patients with flares of chronic obstructive pulmonary disease (COPD) without reducing the chance of treatment success. Before we undertake a large trial to answer these questions, we need to do a small feasibility study to see if our study design will work. The questions we need to answer include:\n\nHow many participants will we able to include in the study over 12 months?\n\nHow many participants in the trial will take all of their medications?\n\nWill study protocols be followed?\n\nHow much information will we be missing at the end of the study?\n\nHow many study participants will take photographs of the phlegm they are coughing up or bring in a sample of the phlegm for inspection by study doctor?\n\nParticipants will:\n\nCome into the clinic to be assessed when they have a flare of COPD, get a chest x-ray, blood work, and a doctor visit. The doctor will provide a prescription if it is a flare of COPD.\n\nThe participant will get a call 3, 14, and 30 days later by a study researcher to ask questions about if the medications have been taken, if cough or shortness of breath remain, and if they have had to seek additional care from another doctor, clinic, or emergency room.",[32,31,29,65,66],"AECOPD","ECOPD",[68,69,70,71,72,73,65,74],"bio-maker","C reactive protein","CRP","eosinophils","exacerbation","COPD exacerbation","biomarker","NOT_YET_RECRUITING","2025-04-08",{"date":78,"type":41},"2025-04-16",{"date":80,"type":23},"2025-09-01",{"date":82,"type":23},"2026-10-01",{"name":84,"class":48},"Ottawa Hospital Research Institute",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":18,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":49},"100572618","respiratory-syncytial-virus-infection-in-exacerbations-of-chronic-obstructive-pulmonary-diasease-the-recode-study-100572618","NCT06735612","Respiratory Syncytial Virus Infection in Exacerbations of Chronic Obstructive Pulmonary Diasease: the RECODE Study","RECODE","Inclusion Criteria:\n\n* Female or male\n* ≥50 years of age\n* Seeking urgent medical attention because of ECOPD, as defined by the Rome consensus definition: \"in a patient with COPD, an exacerbation is an event characterized by dyspnea and\u002For cough and sputum that worsen over \\\u003C14 d, which may be accompanied by tachypnoea and\u002For tachycardia and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways\"\n\nExclusion Criteria:\n\n* Previous RSV vaccination (other vaccines will be allowed and recorded)\n* Active cancer (or any other disease) that may alter the immune status of the patient\n* Neurologic disorders that incapacitate the participation of the patient\n* No signing of the informed consent","50 Years",{"count":94,"type":23},892,"The goal of this observational study is to determine the prevalence of respiratory syncytial virus (RSV) infection and evaluate its association with clinical outcomes in patients with chronic obstructive pulmonary disease (COPD) who experience exacerbations during the RSV season (October-April). The main question it aims to answer is:\n\n* What is the prevalence of RSV infection in patients with COPD during exacerbations in the RSV season?\n* Does RSV infection lead to worse clinical outcomes, including hospitalization, longer length of stay, acute cardiovascular events, and\u002For death in patients with COPD exacerbations?\n\nResearchers will compare patients with RSV infection to those without RSV infection to see if RSV infection results in worse clinical outcomes, such as increased hospitalization, longer stays, cardiovascular events, or death.\n\nParticipants will:\n\n* Be adults diagnosed with COPD who present to the emergency department or day hospital due to acute exacerbations of their respiratory symptoms.\n* Receive treatment as per standard clinical care for COPD exacerbations, including long-acting bronchodilators and inhaled corticosteroids, and may complete a course of antibiotics and\u002For oral corticosteroids if prescribed during hospitalization.\n* Undergo diagnostic testing for RSV infection as part of the clinical routine to determine the presence or absence of the virus during their exacerbation.\n* Have clinical outcomes monitored, including hospitalization rate, length of stay, and any acute cardiovascular events, as well as mortality during the exacerbation period.\n* Provide relevant demographic and clinical data, including medical history, COPD severity, comorbidities, and previous exacerbation events.",[97,31,98,29],"Respiratory Synctial Virus","Chronic Obstructive Pulmonary Disease (COPD)","2025-02-25",{"date":101,"type":41},"2025-02-26",{"date":103,"type":41},"2024-12-16",{"date":105,"type":23},"2025-09",{"name":107,"class":48},"Fundacio Privada Mon Clinic Barcelona"]